InvestorsHub Logo
Followers 36
Posts 6019
Boards Moderated 0
Alias Born 01/28/2010

Re: govprs post# 6901

Tuesday, 08/02/2022 5:13:22 PM

Tuesday, August 02, 2022 5:13:22 PM

Post# of 6939
My guess is Cannell has a deal if Qilu phase 3 data WOULD get approval.the market is worth $12 a share for bladder cancer. If they have any data worth talking about for pancreatic that doubles. That would be a great deal for both parties. Roche, Merck, an AZ will be suitors.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SESN News